Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide, Nivolumab in mesothelioma and ovarian cancer, run by TCR2 Therapeutics, active and no longer recruiting.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer is a phase 1/2 interventional study registered as NCT03907852 by TCR2 Therapeutics, with 57 participants enrolled, started 2019-04-15 and due to reach its primary completion in 2024-11-19. Interventions recorded: gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab. Conditions listed: Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide, Ovarian cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab, Small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Ovarian cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab.
Shares Fludarabine, Mesothelioma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/